Prab: CSV import

2024-03-06T06:29:30Z

CSV import

New page

[[File:AI-10-49.svg|thumb|{{PAGENAME}}]]<br>'''AI-10-49''' is a small molecule inhibitor that specifically targets the [[BRD4]] protein, a member of the [[BET (bromodomain and extra-terminal)]] family of proteins. It was developed by researchers at the [[Dana-Farber Cancer Institute]] and is currently being studied for its potential use in the treatment of various types of [[cancer]].

==Mechanism of Action==

AI-10-49 works by binding to the [[bromodomain]]s of BRD4, thereby inhibiting the protein's ability to bind to [[acetylated]] histones. This disrupts the normal function of BRD4, which plays a key role in the regulation of [[gene expression]] by modulating the structure of [[chromatin]]. By inhibiting BRD4, AI-10-49 can potentially alter the expression of genes that are involved in the growth and proliferation of cancer cells.

==Potential Therapeutic Applications==

The therapeutic potential of AI-10-49 is currently being explored in preclinical studies. Early research suggests that it may be effective in treating various types of cancer, including [[leukemia]], [[lymphoma]], and [[solid tumors]]. In particular, it has shown promise in treating cancers that are driven by the overexpression or mutation of the [[MYC]] oncogene, which is a common feature of many aggressive cancers.

==Clinical Development==

As of now, AI-10-49 is still in the early stages of clinical development. Further studies are needed to determine its safety, efficacy, and optimal dosing regimen in humans. However, the initial results from preclinical studies are promising and suggest that it may have significant potential as a novel cancer therapy.

==See Also==

* [[BET inhibitor]]
* [[Epigenetics in cancer]]
* [[Targeted therapy]]

{{Chemical compounds}}
{{Cancer treatments}}
{{Pharmacology-stub}}

[[Category:Experimental drugs]]
[[Category:Cancer research]]
[[Category:Epigenetics]]
[[Category:Pharmacology]]

AI-10-49 - Revision history

Prab: CSV import